Tumor Biology

, Volume 37, Issue 8, pp 11311–11320 | Cite as

The antitumor effect of TIG3 in liver cancer cells is involved in ERK1/2 inhibition

  • Yan Xu
  • Ting Chen
  • Degui Liao
  • Xiaoqin Wu
  • Yun Zhong
  • Shiming Liu
  • Hui Yang
  • Yuqiang Nie
Original Article


Tazarotene-induced gene 3 (TIG3) was first characterized in tazarotene-treated human keratinocytes and identified as a retinoic acid responder gene, an important mediator of antitumor effects by retinoids. In this study, we aim to investigate the inhibitory effect of TIG3 on the growth of liver cancer and explore its underlying mechanism. Human hepatocellular carcinoma (HCC) Hep3B cells were transfected with plasmid GV141 carrying full-length TIG3 complementary DNA (cDNA). The effects of TIG3 on cell proliferation, apoptosis, and migration were determined in vitro. The suppressor effect of TIG3 on tumor growth was evaluated in vivo in a nude mouse HCC model. We observed that TIG3 expression is decreased in the Hep3B cell line as well as primary HCC tumors, and TIG3 expression inversely correlates with Ki-67 expression. Overexpression of TIG3 suppresses tumor growth in HCC both in vitro and in vivo via ERK1/2 inhibition by promoting apoptosis and inhibiting proliferation and migration. These findings identify TIG3 as an attractive therapeutic target for HCC.


Hepatocellular carcinoma TIG3 ERK Antitumor effect 



This study was supported by grants funded by the Guangdong Natural Science Funds for Distinguished Young Scholar (S2013050014121), National Natural Science Foundation of China (81372634 and 81372633), and the Research Award Fund for Outstanding Young Teachers in Guangdong Provincial Higher Education Institutions (Yq2013133).

Compliance with ethical standards

Human/animal studies have been approved by The Institute of Medical Research Ethics Committee of Guangzhou Medical University. Written consent was obtained from each patient. All human studies were followed in accordance with the ethical standards laid down in 1964 Declaration of Helsinki and its amendments.

Conflicts of interest



  1. 1.
    Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–55.CrossRefPubMedGoogle Scholar
  2. 2.
    El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557–76.CrossRefPubMedGoogle Scholar
  3. 3.
    El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–27.CrossRefPubMedGoogle Scholar
  4. 4.
    Huynh H. Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol. 2010;80:550–60.CrossRefPubMedGoogle Scholar
  5. 5.
    DiSepio D, Ghosn C, Eckert RL, Deucher A, Robinson N, Duvic M, et al. Identification and characterization of a retinoid-induced class ii tumor suppressor/growth regulatory gene. Proc Natl Acad Sci U S A. 1998;95:14811–5.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Scharadin TM, Eckert RL. Tig3: an important regulator of keratinocyte proliferation and survival. J Invest Dermatol. 2014;134:1811–6.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Uyama T, Jin XH, Tsuboi K, Tonai T, Ueda N. Characterization of the human tumor suppressors TIG3 and HRASLS2 as phospholipid-metabolizing enzymes. Biochim Biophys Acta. 2009;1791:1114–24.CrossRefPubMedGoogle Scholar
  8. 8.
    Morales M, Arenas EJ, Urosevic J, Guiu M, Fernandez E, Planet E, et al. RARRES3 suppresses breast cancer lung metastasis by regulating adhesion and differentiation. EMBO Mol Med. 2014;6:865–81.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Errico A. Breast cancer: RARRES3-suppressing metastases to the lung in breast cancer. Nat Rev Clin Oncol. 2014;11:378.CrossRefPubMedGoogle Scholar
  10. 10.
    Scharadin TM, Jiang H, Jans R, Rorke EA, Eckert RL. TIG3 tumor suppressor-dependent organelle redistribution and apoptosis in skin cancer cells. PLoS ONE. 2011;6, e23230.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Huang SL, Shyu RY, Yeh MY, Jiang SY. Cloning and characterization of a novel retinoid-inducible gene 1(RIG1) deriving from human gastric cancer cells. Mol Cell Endocrinol. 2000;159:15–24.CrossRefPubMedGoogle Scholar
  12. 12.
    Kanki K, Akechi Y, Ueda C, Tsuchiya H, Shimizu H, Ishijima N, et al. Biological and clinical implications of retinoic acid-responsive genes in human hepatocellular carcinoma cells. J Hepatol. 2013;59:1037–44.CrossRefPubMedGoogle Scholar
  13. 13.
    Yang H, Zhan Q, Wan YJ. Enrichment of Nur77 mediated by retinoic acid receptor beta leads to apoptosis of human hepatocellular carcinoma cells induced by fenretinide and histone deacetylase inhibitors. Hepatology. 2011;53:865–74.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Okuno M, Kojima S, Matsushima-Nishiwaki R, Tsurumi H, Muto Y, Friedman SL, et al. Retinoids in cancer chemoprevention. Curr Cancer Drug Targets. 2004;4:285–98.CrossRefPubMedGoogle Scholar
  15. 15.
    Haroon S, Hashmi AA, Khurshid A, Kanpurwala MA, Mujtuba S, Malik B, et al. Ki67 index in breast cancer: correlation with other prognostic markers and potential in Pakistani patients. Asian Pac J Cancer Prev. 2013;14:4353–8.CrossRefPubMedGoogle Scholar
  16. 16.
    Jiang SY, Chou JM, Leu FJ, Hsu YY, Shih YL, Yu JC, et al. Decreased expression of type ii tumor suppressor gene RARRES3 in tissues of hepatocellular carcinoma and cholangiocarcinoma. World J Gastroenterol. 2005;11:948–53.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Mu H, Lin KX, Zhao H, Xing S, Li C, Liu F, et al. Identification of biomarkers for hepatocellular carcinoma by semiquantitative immunocytochemistry. World J Gastroenterol. 2014;20:5826–38.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Wu CC, Shyu RY, Chou JM, Jao SW, Chao PC, Kang JC, et al. RARRES1 expression is significantly related to tumour differentiation and staging in colorectal adenocarcinoma. Eur J Cancer. 2006;42:557–65.CrossRefPubMedGoogle Scholar
  19. 19.
    Yang H, Nie Y, Li Y, Wan YJ. Histone modification-mediated CYP2E1 gene expression and apoptosis of HepG2 cells. Exp Biol Med (Maywood). 2010;235:32–9.CrossRefGoogle Scholar
  20. 20.
    Alizadeh F, Bolhassani A, Khavari A, Bathaie SZ, Naji T, Bidgoli SA. Retinoids and their biological effects against cancer. Int Immunopharmacol. 2014;18:43–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Bu P, Wan YJ. Fenretinide-induced apoptosis of Huh-7 hepatocellular carcinoma is retinoic acid receptor beta dependent. BMC Cancer. 2007;7:236.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Wang S, Jiang W, Chen X, Zhang C, Li H, Hou W, et al. Alpha-fetoprotein acts as a novel signal molecule and mediates transcription of Fn14 in human hepatocellular carcinoma. J Hepatol. 2012;57:322–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Yan TD, Wu H, Zhang HP, Lu N, Ye P, Yu FH, et al. Oncogenic potential of retinoic acid receptor-gamma in hepatocellular carcinoma. Cancer Res. 2010;70:2285–95.CrossRefPubMedGoogle Scholar
  24. 24.
    Kawakami S, Suzuki S, Yamashita F, Hashida M. Induction of apoptosis in A549 human lung cancer cells by all-trans retinoic acid incorporated in DOTAP/cholesterol liposomes. J Control Release. 2006;110:514–21.CrossRefPubMedGoogle Scholar
  25. 25.
    Higuchi E, Chandraratna RA, Hong WK, Lotan R. Induction of TIG3, a putative class ii tumor suppressor gene, by retinoic acid in head and neck and lung carcinoma cells and its association with suppression of the transformed phenotype. Oncogene. 2003;22:4627–35.CrossRefPubMedGoogle Scholar
  26. 26.
    Duvic M, Ni X, Talpur R, Herne K, Schulz C, Sui D, et al. Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application. J Invest Dermatol. 2003;121:902–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Yip-Schneider MT, Klein PJ, Wentz SC, Zeni A, Menze A, Schmidt CM. Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells. J Pharmacol Exp Ther. 2009;329:1063–70.CrossRefPubMedGoogle Scholar
  28. 28.
    Huynh H, Soo KC, Chow PK, Tran E. Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma. Mol Cancer Ther. 2007;6:138–46.CrossRefPubMedGoogle Scholar
  29. 29.
    Davies BR, Logie A, McKay JS, Martin P, Steele S, Jenkins R, et al. Azd6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther. 2007;6:2209–19.CrossRefPubMedGoogle Scholar
  30. 30.
    Huynh H, Nguyen TT, Chow KH, Tan PH, Soo KC, Tran E. Over-expression of the mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK in hepatocellular carcinoma: its role in tumor progression and apoptosis. BMC Gastroenterol. 2003;3:19.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  1. 1.Department of Gastroenterology and Hepatology, First Municipal’s People Hospital of GuangzhouGuangzhou Medical UniversityGuangzhouChina
  2. 2.Department of Gastroenterology, Second Affiliated HospitalGuangzhou Medical UniversityGuangzhouChina
  3. 3.Department of Pathology, Second Affiliated HospitalGuangzhou Medical UniversityGuangzhouChina
  4. 4.Guangzhou Institute of Cardiovascular DiseaseGuangzhouChina

Personalised recommendations